Quoin Pharmaceuticals Announces FDA Fast Track Designation For QRX003 For The Treatment Of Peeling Skin Syndrome - QNRX News | RalliesQuoin Pharmaceuticals Announces FDA Fast Track Designation For QRX003 For The Treatment Of Peeling Skin Syndrome
Q
QNRX• FDA Fast Track for QRX003
- Quoin Pharmaceuticals announces FDA Fast Track designation for QRX003 for the treatment of peeling skin syndrome.
- Quoin Pharmaceuticals said it plans to initiate a Phase 2/3 study of QRX003 in peeling skin syndrome in the second half of 2026.
•
